ClinConnect ClinConnect Logo
Search / Trial NCT03498053

Smoking Topography Study 2018

Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Apr 6, 2018

Trial Information

Current as of June 08, 2025

Completed

Keywords

ClinConnect Summary

In 2005, the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) was established with the aim for a regulatory strategy as a response to the globalization of the tobacco epidemic. One of their non-price measures to reduce the demand for tobacco includes article 9: Regulation of the contents of tobacco products . Cigarette product regulation is currently based on tar, nicotine and carbon monoxide (TNCO) levels in cigarette smoke, which are indicated on the package. This is not sufficient, since cigarette smoke includes more than 7000 chemicals. There are aldehydes, V...

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Male
  • 25-35 years old (birth year 1982 - 1992)
  • Caucasian
  • Smoking Marlboro as usual brand for at least 3 years
  • Used to smoke between 13 and 25 cigarettes a day (around a package/day)
  • Exclusion Criteria:
  • Heavy smoker (minimum of 25 cigarettes/day)
  • Smokes more than 1 brand on a regular base.
  • Amount of cigarettes per day varies ±10, between days
  • Daily medication use
  • Experienced adverse effects due to smoking
  • Suffering chronic illness

About Maastricht University Medical Center

Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.

Locations

Maastricht, , Netherlands

Patients applied

0 patients applied

Trial Officials

Agnes Boots, PhD

Principal Investigator

Maastricht University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials